MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
MediWound (Nasdaq: MDWD) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and business highlights.
Dial-in numbers and a live webcast link are provided, and an archived replay will be available on the company's Investors website.
Positive
- None.
Negative
- None.
News Market Reaction – MDWD
On the day this news was published, MDWD gained 0.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MDWD was down 3.39% while close biotechnology peers were mixed, with names like TLSA up 2.19% and NTHI down 1.97%, indicating stock-specific trading rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Investor conferences | Positive | +2.6% | Upcoming presentations at major healthcare investor conferences with webcasts. |
| Jan 12 | Corporate outlook | Positive | -7.9% | Corporate update with clinical progress and multi‑year revenue guidance. |
| Dec 10 | Clinical data | Positive | +3.8% | New clinical data showing NexoBrid effectiveness in preventing traumatic tattoos. |
| Nov 20 | Earnings release | Neutral | -5.6% | Q3 2025 results with revenue growth, facility expansion, and equity financing. |
| Nov 05 | Earnings date | Neutral | +1.4% | Announcement of Q3 2025 results date and related conference call details. |
Recent history shows generally positive reactions to clinical and event announcements, with at least one notable selloff following a broadly positive corporate and financial outlook update.
Over the past several months, MediWound has combined clinical, financial, and corporate milestones. In November 2025, Q3 results showed rising revenue and an equity raise, followed by an updated multi‑year outlook on January 12, 2026 that included 2025 revenue of $17M and higher guidance through 2028. Clinical data for NexoBrid released on December 10, 2025 was well received, while conference participation and prior earnings-date notices had modest positive impacts. Today’s announcement simply sets the timetable for the next earnings release, fitting a pattern of routine communications around financial reporting.
Market Pulse Summary
This announcement sets the schedule for MediWound’s fourth quarter and full-year 2025 results on March 5, 2026, with a conference call at 8:30 a.m. ET. Investors may compare the upcoming figures to the preliminary 2025 revenue and multi‑year guidance furnished on January 12, 2026, as well as the Q3 2025 results and recent clinical progress for NexoBrid and EscharEx. Attention typically focuses on updated revenue trends, cash position, and any revisions to previously communicated outlooks.
AI-generated analysis. Not financial advice.
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time
YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026.
Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide business highlights.
Conference Call & Webcast Details
Toll-Free: 1-844-676-8833
Israel: 1-80-921-2373
International: 1-412-634-6869
Webcast: Click HERE
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.
For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).
MediWound Contacts:
Hani Luxenburg Daniel Ferry
Chief Financial Officer Managing Director
MediWound Ltd. LifeSci Advisors, LLC
ir@mediwound.com daniel@lifesciadvisors.com
FAQ
When will MediWound (MDWD) release Q4 and full year 2025 results and when is the conference call?
How can investors access the MediWound (MDWD) conference call and webcast on March 5, 2026?
Will a replay of the MediWound (MDWD) March 5, 2026 webcast be available and where can I find it?
What topics will MediWound management cover on the March 5, 2026 earnings call for MDWD?
What telephone numbers should international investors use to join the MediWound (MDWD) March 5, 2026 call?
